Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Build status - In Progress

Enrolling By Invitation

18 years - 99 years

Female

Phase N/A

200 participants needed

1 Location

Brief description of study

This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer or vincristine for lymphoma. Participants will be enrolled over approximately 1-year.The purpose of this present study is to prospectively collect clinical and biomarker data from patients receiving neurotoxic chemotherapy who are at risk for developing CIPN.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: breast cancer,taxane
Age: 18 years - 99 years
Gender: Female

Updated on 04 Aug 2024. Study ID: 833120

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research